Onco-Innovations Partners with Ifowonco for LAG-3 Inhibitor Program

Onco-Innovations Limited has entered into a non-binding Letter of Intent with Ifowonco Informatics Incorporated. This initial step could lead to a definitive agreement, giving Onco an exclusive option to Ifowonco's LAG-3 small-molecule inhibitor program. This collaboration aims to merge Ifowonco's immune checkpoint technology with Onco's expertise in DNA damage response therapies.

LAG-3 plays a role in T-cell regulation. Ifowonco's inhibitors target this protein and aim to restore immune activity against cancer. The collaboration hopes to evaluate this program's potential when combined with Onco's DNA damage response therapy, ONC010.

Ifowonco's approach focuses on oral small-molecule inhibitors, differing from existing intravenous monoclonal antibody therapies. This could enhance patient convenience and treatment flexibility. Onco's CEO expressed excitement about this partnership's potential to position the company in next-gen cancer immunotherapy.